跳至主要内容
临床试验/JPRN-UMIN000027623
JPRN-UMIN000027623已完成未知

Radiotherapy for glioblastoma: Dose escalation trial of IMRT after hyperbaric oxygen therapy - Dose escalation trial of IMRT after hyperbaric oxygen for glioblastoma

Tobata Kyoritsu Hospital0 个研究点目标入组 18 人开始时间: 2017年6月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Without brain stem invasion. Gliomatosis cerebri

研究者

相似试验

已完成
1 期
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaAstrocytoma, Grade IVGiant Cell GlioblastomaGliosarcomaGlioblastoma Multiforme
NCT02709226National Cancer Institute (NCI)17
招募中
3 期
Glioblastoma, Optimizing Logistics and Dose (GOLD).glioblastoma10029211brain tumor
NL-OMON52680niversitair Medisch Centrum Utrecht474
招募中
3 期
Re-irradiation of recurrent Glioblastoma withCarbon-Ions (C12) versus Stereotactic Radiotherapy with Photons - A Multicenter, Prospective Randomized Two-Arm TrialC71.9Brain, unspecified
DRKS00025069Philipps-Universität Marburg190
尚未招募
不适用
Phase I study of radiotherapy dose escalation on the 18F-FDG-PET avid region of the primary tumor in locally advanced oropharynx and oral cavity tumors eligible for concurrent chemoradiation.Cancer of the mouth and throatoropharynx/oral cavity carcinoma`s10017991
NL-OMON33780Antoni van Leeuwenhoek Ziekenhuis30
进行中(未招募)
不适用
First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-VaxPatients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide.MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-015979-27-ATActivartis Biotech GmbH76